secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0000950170-24-003376
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports $719.9M cash; launches 'OnTarget 2026' plan targeting first approval in 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $719.9M as of Dec 31, 2023 (unaudited); expected to fund operations into 2027.
- OnTarget 2026 plan aims for first potential approved product in 2026, with pivotal data from at least one lead program in 2025.
- 2024 milestones: advance Phase 2 ARROS-1 (NVL-520) and initiate Phase 2 ALKOVE-1 (NVL-655), launch front-line ALK strategy, start Phase 1 for HER2 program.
- Interim data from ARROS-1 and ALKOVE-1 expected at medical meetings in 2024.
- Company to present at J.P. Morgan Healthcare Conference on Jan 9, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024003376/0000950170-24-003376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024003376/nuvl-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-003376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer